Sun Pharmaceutical Industries Limited vs Laurus Labs Limited

An objective side-by-side of SUNPHARMA and LAURUSLABS, both in Pharmaceuticals - Indian - Bulk Drugs & Formln: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.

Prices as of 2026-10-16 close Latest results: SUNPHARMA Jun 2026 · LAURUSLABS Jun 2026

At a glance

  • Sun Pharmaceutical Industries Limited is the larger company by market value, about 3.8 times the size of Laurus Labs Limited.
  • On trailing earnings, Sun Pharmaceutical Industries Limited trades at the lower P/E (34.9 against 102.1).
  • Laurus Labs Limited earns the higher return on equity (20.6% against 14.5%).
  • Over three years Sun Pharmaceutical Industries Limited has grown profits faster (13% a year against 4%).
  • Over the past year the share prices returned +5.3% (SUNPHARMA) and +135.0% (LAURUSLABS).
Metric Sun Pharmaceutical
SUNPHARMA
Laurus Labs
LAURUSLABS
Size and price
Market cap₹421,995 Cr₹111,310 Cr
Share price₹1,758.80₹2,060.10
Valuation
P/E34.86102.09
P/B5.0521.00
EV/EBITDA23.9055.97
PEG2.6825.52
Dividend yield0.9%0.1%
Profitability
ROE14.5%20.6%
ROCE21.0%18.0%
Operating margin29.8%28.0%
Sales (TTM)₹59,911 Cr₹7,270 Cr
Net profit (TTM)₹12,104 Cr₹1,090 Cr
Growth
Latest quarter sales YoY+10.5%+29.1%
Latest quarter profit YoY+27.0%+123.9%
Sales CAGR 3Y+10.0%+4.0%
Profit CAGR 3Y+13.0%+4.0%
Sales CAGR 5Y+12.0%+7.0%
Profit CAGR 5Y+17.0%-2.0%
Financial strength
Debt/Equity0.060.48
Interest cover43.647.62
Ownership
Promoter holding52.7%27.5%
Promoter change (4 qtrs)-1.80 pp-0.13 pp
Price performance
Return 1M-5.11%+8.11%
Return 3M-8.99%+34.66%
Return 1Y+5.26%+134.97%
Return YTD+2.27%+85.93%
Technical condition
Technical score2687
RS rating (1-99)57.0095.00
% vs 200-DMA-2.73%+46.73%
RSI (14)37.0160.45
% from 52-week high-14.07%-1.24%

Go deeper on each company

Related comparisons

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI